ArticleScientific reports2025
UPLC-QqQMS based targeted metabolomics reveal combination impact on metabolism caused by bisphenol AF and fructose combined exposure in male mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bisphenol AF (BPAF), a fluorinated alternative to the plasticizer bisphenol A (BPA), is found in both the environment and the human body. Fructose is one of the sweeteners that has been widely used in recent years. Prior research has verified that the combined exposure to fructose and BPA considerably worsened the impact on glycolipid metabolism. However, it is currently unclear whether BPAF have a combination effect on health with fructose. Serum glucose and insulin, liver biochemistry, histology of the liver and adipose tissue, serum profiles of amino acids, vitamins, bile acids, steroid hormones, catecholamines, and adipocytokines like leptin, omentin-1, adiponectin, asprosin, and adipocyte fatty acid binding protein (A-FABP) of male mice were all investigated in this study following a week of combined exposure to two doses of BPAF (lower dose: 0.25, and higher dose: 25 μg/kg daily). The results showed that simultaneous exposure to lower doses of BPAF and fructose considerably increased blood insulin and liver coefficient, total bilirubin, direct bilirubin, and glucose while significantly decreasing body weight, food intake, liver creatinine, and serum leptin, asprosin, and A-FABP. According to histology analysis, adipocyte enlargement may result from lower dose BPAF and fructose combined exposure, while bile duct dilatation may result from both lower and higher doses of BPAF combined with fructose. Concurrently, the combination of lower doses of BPAF and fructose increased the release of adrenocortical hormones and catecholamines, worsened metabolic disorders in amino acids such as histidine, arginine and proline, branched chain amino acid (isoleucine), and aromatic amino acids (tryptophan and phenylalanine), and aggravated the depletion of vitamin B12 and A. Interestingly, following the combined exposure to BPAF and fructose, bile acids including taurocholic acid, deoxycholic acid, cholic acid, and taurine ursodeoxycholic acid rose in a dose-dependent manner. According to these results, exposure to fructose and BPAF together may have a more detrimental effect on metabolism than either substance alone. Further research should be conducted to verify the impact of joint exposure to BPAF and fructose on human.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.